Enhancing surgical vision by using real-time imaging of αvβ3-integrin targeted near-infrared fluorescent agent

Annals of Surgical Oncology

Volumn 18, Issue 12, 2011, Pages 3506-3513

  Themelis, George ^a   Harlaar, Niels J ^a,b   Kelder, Wendy ^b   Bart, Joost ^b   Sarantopoulos, Athanasios ^a   Dam, Gooitzen M Van ^b   Ntziachristos, Vasilis ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRAST MEDIUM; FLUORESCENT DYE; INTEGRISENSE 680; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOLUMINESCENCE; CANCER SURGERY; CANCER TISSUE; CONTROLLED STUDY; EX VIVO STUDY; FEMALE; FLUORESCENCE EPI ILLUMINATION IMAGING; FLUORESCENCE IMAGING; FLUORESCENT ANTIBODY TECHNIQUE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMAGING SYSTEM; IN VIVO STUDY; MOLECULAR IMAGING; MOLECULAR PROBE; MOUSE; NONHUMAN; PROTEIN TARGETING; SENSITIVITY AND SPECIFICITY; SIGNAL NOISE RATIO; WHITE LIGHT;

EID: 85027922455     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-011-1664-9     Document Type: Article

References (49)

1. Fang W, Chen W, Chen G, et al. Surgical management of thymic epithelial tumors: a retrospective review of 204 cases. Ann Thorac Surg. 2005;80(6):2002-7.
2. Mendenhall WM, Zlotecki RA, Hochwald SN, et al. Retroperitoneal soft tissue sarcoma. Cancer. 2005;104(4):669-75.
3. Pitz CC, de la Riviere AB, van Swieten HA, et al. Surgical treatment of Pancoast tumours. Eur J Cardiothorac Surg. 2004;26(1):202-8.
4. Pendlebury SC, Ivanov O, Renwick S, et al. Long-term review of a breast conservation series and patterns of care over 18 years. ANZ J Surg. 2003;73(8):577-83.
5. Kestin LL, Goldstein NS, Lacerna MD, et al. Factors associated with local recurrence of mammographically detected ductal carcinoma in situ in patients given breast-conserving therapy. Cancer. 2000;88(3):596-607.
6. Lacquet LK. The present status of surgery for lung cancer. Acta Chir Belg. 1996;96(6):245-51.
7. Gage I, Schnitt SJ, Nixon AJ, et al. Pathologic margin involvement and the risk of recurrence in patients treated with breastconserving therapy. Cancer. 1996;78(9):1921-8.
8. Pleijhuis RG, Graafland M, de Vries J, et al. Obtaining adequate surgical margins in breast-conserving therapy for patients with early-stage breast cancer: current modalities and future directions. Ann Surg Oncol. 2009;16:2717-2730.
9. de Gara CJ, Hanson J, Hamilton S. A population-based study of tumor-node relationship, resection margins, and surgeon volume on gastric cancer survival. Am J Surg. 2003;186(1):23-7.
10. Cao D, Lin C, Woo SH, et al. Separate cavity margin sampling at the time of initial breast lumpectomy significantly reduces the need for reexcisions. Am J Surg Pathol. 2005;29(12):1625-32.
11. Di Musto PD, Orringer MB. Transhiatal esophagectomy for distal and cardia cancers: implications of a positive gastric margin. Ann Thorac Surg. 2007;83(6):1993-8 (discussion 1998-9)
12. Wray CJ, Ahmad SA, Matthews JB, et al. Surgery for pancreatic cancer: recent controversies and current practice. Gastroenterology. 2005;128(6):1626-41.
13. Braat AE, Oosterhuis JW, de Vries JE, et al. Lymphatic staging in colorectal cancer: pathologic, molecular, and sentinel node techniques. Dis Colon Rectum. 2005;48(2):371-83.
14. Adamovich TL, Simmons RM. Ductal carcinoma in situ with microinvasion. Am J Surg. 2003;186(2):112-6.
15. Juretzka MM, Chi DS, Sonoda Y. Update on surgical treatment for endometrial cancer. Expert Rev Anticancer Therapy. 2005;5(1):113-21.
16. Smeets A, Christiaens MR. Implications of the sentinel lymph node procedure for local and systemic adjuvant treatment. Curr Opin Oncol. 2005;17(6):539-44.
17. Roukos DH, Kappas AM. Perspectives in the treatment of gastric cancer. Nat Clin Pract Oncol. 2005;2(2):98-107.
18. Tsukamoto T, Kitamura H, Takahashi A, et al. Treatment of invasive bladder cancer: lessons from the past and perspective for the future. Jpn J Clin Oncol. 2004;34(6):295-306.
19. Kabuto M, Kubota T, Kobayashi H, et al. Experimental and clinical study of detection of glioma at surgery using fluorescent imaging by a surgical microscope after fluorescein administration. Neurol Res. 1997;19(1):9-16.
20. Moore GE. Fluorescein as an agent in the differentiation of normal and malignant tissues. Science. 1947;106(2745):130-1.
21. Stummer W, Reulen HJ, Novotny A, et al. Fluorescence-guided resections of malignant gliomas-an overview. Acta Neurochir Suppl. 2003;88:9-12.
22. Stummer W, Stocker S, Wagner S, et al. Intraoperative detection of malignant gliomas by 5-aminolevulinic acid-induced porphyrin fluorescence. Neurosurgery. 1998;42(3):518-25; discussion 525-6
23. Haglund MM, Berger MS, Hochman DW. Enhanced optical imaging of human gliomas and tumor margins. Neurosurgery. 1996;38(2):308-17.
24. Kremer P, Wunder A, Sinn H, et al. Laser-induced fluorescence detection of malignant gliomas using fluorescein-labeled serum albumin: experimental and preliminary clinical Results. Neurol Res. 2000;22(5):481-9.
25. Kircher MF, Mahmood U, King RS, et al. A multimodal nanoparticle for preoperative magnetic resonance imaging and intraoperative optical brain tumor delineation. Cancer Res. 2003;63(23):8122-5.
26. Adusumilli PS, Stiles BM, Chan MK, et al. Real-time diagnostic imaging of tumors and metastases by use of a replication-competent herpes vector to facilitate minimally invasive oncological surgery. FASEB J. 2006;20(6):726-8.
27. Stummer W, Novotny A, Stepp H, et al. Fluorescence-guided resection of glioblastoma multiforme by using 5-aminolevulinic acid-induced porphyrins: a prospective study in 52 consecutive patients. J Neurosurg. 2000;93(6):1003-13.
28. Eisenberg DP, Adusumilli PS, Hendershott KJ, et al. Real-time intraoperative detection of breast cancer axillary lymph node metastases using a green fluorescent protein-expressing herpes virus. Ann Surg. 2006;243(6):824-30 (discussion 830-2).
29. Tanaka E, Choi HS, Fujii H, et al. Image-guided oncologic surgery using invisible light: completed pre-clinical development for sentinel lymph node mapping. Ann Surg Oncol. 2006;13(12):1671-81.
30. Sato K, Nariai T, Sasaki S, et al. Intraoperative intrinsic optical imaging of neuronal activity from subdivisions of the human primary somatosensory cortex. Cereb Cortex. 2002;12(3):269-80.
31. Haglund MM, Hochman DW. Imaging of intrinsic optical signals in primate cortex during epileptiform activity. Epilepsia. 2007;48(Suppl 4): 65):65-74.
32. Nakayama A, del Monte F, Hajjar RJ, et al. Functional nearinfrared fluorescence imaging for cardiac surgery and targeted gene therapy. Mol Imaging. 2002;1(4):365-77.
33. Bogaards A, Varma A, Collens SP, et al. Increased brain tumor resection using fluorescence image guidance in a preclinical model. Lasers Surg Med. 2004;35(3):181-90.
34. Ray ER, Chatterton K, Khan MS, et al. Hexylaminolaevulinate 'blue light' fluorescence cystoscopy in the investigation of clinically unconfirmed positive urine cytology. BJU Int. 2009;103(10):1363-7.
35. Bogaards A, Varma A, Collens SP, et al. Increased brain tumor resection using fluorescence image guidance in a preclinical model. Lasers Surg Med. 2004;35(3):181-90.
36. Stummer W, Novotny A, Stepp H, et al. Fluorescence-guided resection of glioblastoma multiforme by using 5-aminolevulinic acid-induced porphyrins: a prospective study in 52 consecutive patients. J Neurosurg. 2000;93(6):1003-13.
37. Ntziachristos V, Ripoll J, Wang LV, et al. Looking and listening to light: the evolution of whole-body photonic imaging. Nat Biotechnol. 2005;23(3):313-20.
38. Yang VX, Muller PJ, Herman P, et al. A multispectral fluorescence imaging system: design and initial clinical tests in intraoperative Photofrin-photodynamic therapy of brain tumors. Lasers Surg Med. 2003;32(3):224-32.
39. Ntziachristos V, Turner G, Dunham J, et al. Planar fluorescence imaging using normalized data. J Biomed Opt. 2005;10(6):064007.
40. Bogaards A, Sterenborg HJ, Trachtenberg J, et al. In vivo quantification of fluorescent molecular markers in real-time by ratio imaging for diagnostic screening and image-guided surgery. Lasers Surg Med. 2007;39(7):605-13.
41. Themelis G, Yoo JS, Ntziachristos V. Multispectral imaging using multiple-bandpass filters. Opt Lett. 2008;33(9):1023-5.
42. Themelis G, Yoo JS, Soh KS, et al. Real-time intraoperative fluorescence imaging system using light-absorption correction. J Biomed Opt. 2009;14(6):064012.
43. Vellon L, Menendez JA, Lupu R. AlphaVbeta3 integrin regulates heregulin (HRG)-induced cell proliferation and survival in breast cancer. Oncogene. 2005;24(23):3759-73.
44. Rabb H, Barroso-Vicens E, Adams R, et al. Alpha-V/beta-3 and alpha-V/beta-5 integrin distribution in neoplastic kidney. Am J Nephrol. 1996;16(5):402-8.
45. Pecheur I, Peyruchaud O, Serre CM, et al. Integrin alpha (v) beta3 expression confers on tumor cells a greater propensity to metastasize to bone. FASEB J. 2002;16(10):1266-8.
46. Gasparini G, Brooks PC, Biganzoli E, et al. Vascular integrin alpha (v) beta3: a new prognostic indicator in breast cancer. Clin Cancer Res. 1998;4(11):2625-34.
47. Kossodo S, Pickarski M, Lin SA, et al. Dual in vivo quantification of integrin-targeted and protease-activated agents in cancer using fluorescence molecular tomography (FMT). Mol Imaging Biol. 12(5):488-99.
48. Weissleder R, Tung CH, Mahmood U, et al. In vivo imaging of tumors with protease-activated near-infrared fluorescent probes. Nat Biotechnol. 1999;17(4):375-8.
49. Razansky D. Multispectral opto-acoustic tomography of deepseated fluorescent proteins in vivo. Nat Photon. 2009;3:412-417.